Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 8/20 | 0.35 |
| ▸ | MMP8 | P22894 | 4/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000208 | 1.00 | S1PR1 (0.39) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL5999897 | 0.87 | S1PR1 (0.40) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL5999898 | 0.87 | S1PR1 (0.40) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL27650657 | 0.83 | ACE (0.34) | ACEMMP8MMP3MMP13ABCB11 | |
| SCHEMBL5999037 | 0.83 | S1PR1 (0.37) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL5999041 | 0.83 | S1PR1 (0.37) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL6000132 | 0.78 | NR4A2 (0.39) | S1PR1PTPN1MMP8MMP3 | |
| SCHEMBL6000125 | 0.78 | NR4A2 (0.39) | S1PR1PTPN1MMP8MMP3 | |
| SCHEMBL6001122 | 0.72 | NAMPT (0.37) | S1PR1PTPN1ACEMMP8MMP3 | |
| SCHEMBL6001128 | 0.72 | NAMPT (0.37) | S1PR1PTPN1ACEMMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | S1PR1 740/4885PTPN1 2/4885ACE 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.